camonsertib   Click here for help

GtoPdb Ligand ID: 12073

Synonyms: RP-3500 | RP3500
Compound class: Synthetic organic
Comment: RP-3500 is a clinical lead, selective ATR (Ataxia telangiectasia and Rad3-related) serine/threonine kinase inhibitor that was developed as a novel oncology therapeutic [1]. We matched RP-3500's chemical structure to the INN 'camonsertib' that was included in the WHO's proposed INN list 127 (21 July 2022).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 100.8
Molecular weight 410.21
XLogP 3.25
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@@H]1COCCN1c1cc(c2c(n1)n(nc2)c1ccn[nH]1)C1(O)C[C@@H]2CC[C@H](C1)O2
Isomeric SMILES C[C@@H]1COCCN1c1nc2c(cnn2c2ccn[nH]2)c(c1)C1(C[C@H]2CC[C@@H](C1)O2)O
InChI InChI=1S/C21H26N6O3/c1-13-12-29-7-6-26(13)19-8-17(21(28)9-14-2-3-15(10-21)30-14)16-11-23-27(20(16)24-19)18-4-5-22-25-18/h4-5,8,11,13-15,28H,2-3,6-7,9-10,12H2,1H3,(H,22,25)/t13-,14-,15+,21?/m1/s1
InChI Key YIHHYCIYAIVQKX-YNOVCBQDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
RP-3500 has been advanced to early stage clinical studies in which it will be evaluated for efficacy against advanced cancers, in particular those with DNA damage response defects. It will be tested as a monotherapy and in combinations with existing PARP inhibitors (niraparib, olaparib, talazoparib), gemcitabine or the PKMYT1 inhibitor (S)-RP-6306.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04972110 Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors Phase 1/Phase 2 Interventional Repare Therapeutics
NCT05405309 RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia Phase 1/Phase 2 Interventional University of Utah
NCT04855656 Study of RP-6306 Alone or in Combination With RP-3500 in Patients With Advanced Solid Tumors Phase 1 Interventional Repare Therapeutics
NCT04497116 Study of RP-3500 in Advanced Solid Tumors Phase 1/Phase 2 Interventional Repare Therapeutics